Evaluation of multidisciplinary treatment of bladder cancer, especially in chemoimmunotherapy (ADM and OK-432) as a consolidation therapy
Tóm tắt
The relapse rate of bladder cancer (transitional cell Ca) is said to be about 45%–80% even after tumor resection. Multidisciplinary treatment was designed and studied to prevent such recurrence. This treatment was designed to have three steps: induction, consolidation, and maintenance therapy. Following surgical tumor removal, OK-432 and Adriamycin (ADM) were administered as consolidation therapy, followed by administration of PSK and carboquone (CQ) in small amounts as maintenance therapy continuously for about 3 years, and the course was observed. In both consolidation and maintenance groups various non-specific immunoparameters were superior in groups receiving combined immunotherapeutic agents. Thus, the use of immunotherapeutic agents in combination with chemotherapeutic agents was considered to be effective. The 3-year recurrence rate was only 8% in the multidisciplinary treatment group, while that in the non-multidisciplinary treatment group was 61%. This approach, especially with chemoimmunotherapy (ADM and OK-432) as a consolidation therapeutic mode, is therefore considered to be useful for the prevention of recurrence.
Tài liệu tham khảo
Carter SK, Wasserman TH (1975) The chemotherapy of urologic cancer. Cancer 36: 729–747
Cohen J (1969) Statistical power analysis for the behavioral sciences. Academic Press, New York
Dekernion JB, Skinner DG (1978) Epidemiology, diagnosis, and staging of bladder cancer. In: Skinner DG (ed) Genitourinary cancer. Saunders, Philadelphia London Toronto, pp 213–231
Gehan EA, Freireich EJ (1974) Non-randomized controls in cancer clinical trials. N Engl J Med 290: 198–203
Hoshino T, Uchida A, et al (1976) Immunotherapy of cancer with immunostimulants. Jpn J Clin Immunol 8: 1105–1114
Karnofsky DA (1961) Meaningful clinical classification of therapeutic responses to anticancer drugs. Clin Pharmacol Ther 2: 709–712
Mathé G, et al (1969) Active immunotherapy for acute lymphoblastic leukemia. Lancet I: 697
Morton DL, et al (1974) BCG immunotherapy of malignant melanoma. Summary of seven year's experience. Ann Surg 180: 635
Nakagami Y, et al (1978a) Adjuvant immunotherapy with antitumor Str. pyogenes preparation in urogenital carcinoma. J Nippon Med Sch 45: 284–286
Nakagami Y, et al (1978b) Adjuvant immunotherapy with antitumor Str. pyogenes preparation in urogenital carcinoma. (Abstract) XIIth International Congress of Cancer in Buenos Aires, Workshop #28 No. 2, 71
Nakagami Y, et al (1979) Adjuvant immunotherapy with antitumor Str. pyogenes preparation (immunopotentiator OK-432) in urogenital carcinoma. Acta Urol Jap 25: 133–141
Niijima T (1978) Intravesical therapy with adriamycin and new trends in the diagnostics and therapy of superficial urinary bladder tumours. WHO center meeting records, pp 37–44
Persky L, Krush ED, Soloway M (1978) Urotherlial tumors. In: Devine CJ Jr (ed) Urology in practice. Little, Brown, Boston, pp 653–690
Turner AG, Durrant KR, Malpas JS (1979) A trial of bleomycin versus adriamycin in advanced carcinoma of the bladder. Br J Urol 51: 121–124
Union Internationale Contre le Cancer (1978) TNM classification of malignant tumors. UICC, Geneve, pp 113–117
Wallace DM, Bloom HJG (1976) The management of deeply infiltrating (T3) bladder carcinoma: Controlled trial of radical radiotherapy versus preoperative radiotherapy and radical cystectomy (First report). Br J Urol 48: 587–594
Weinstein SH, Schmidt JD (1976) Doxorubicin chemotherapy in advanced transitional cell carcinoma. Urology 8: 336–341
Yagoda A, Watson RC, Whitmore WF, Grabstald H, Middleman MP, Krakoff IH (1977) Adriamycin in advanced urinary tract cancer. Cancer 39: 279–285
Yata J (1978) Cells involved in immune responses and their rules. Jpn J Dermatol [B] 88: 607–613